A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.

@article{Streim2008ARD,
  title={A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease.},
  author={Joel E. Streim and Anton P. Porsteinsson and Christopher D Breder and Ren{\'e} Swanink and Ronald N. Marcus and Robert D. McQuade and William H. Carson},
  journal={The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry},
  year={2008},
  volume={16 7},
  pages={537-50}
}
OBJECTIVE To evaluate the efficacy and safety of aripiprazole treatment for psychotic symptoms associated with Alzheimer disease (AD). METHODS In this parallel group, randomized, double-blind, placebo-controlled, flexible-dose trial, institutionalized subjects with AD and psychotic symptoms were randomized to aripiprazole (n = 131) or placebo (n = 125) for 10 weeks. The aripiprazole starting dose was 2 mg/day, and could be titrated to higher doses (5, 10, and 15 mg/day) based on efficacy and… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 18 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 53 references

Quetiapine to treat agitaStreim et al

  • KX Zhong, PN Tariot, J Mintzer
  • Am J Geriatr Psychiatry
  • 2008

Overall Safety of Aripiprazole in Trials of Patients with Psychosis of Alzheimer’s Dementia

  • C Breder, D Kostic, A Forbes
  • American Psychiatric Association,
  • 2005

Similar Papers

Loading similar papers…